A study to investigate the relative bioavailability of AZD8630 following a device and formulation transition in healthy participants.

Study identifier:D6830C00002

ClinicalTrials.gov identifier:NCT06531811

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Randomized, Open-label, Single-dose, 2-Treatment, 2-Period, Crossover Study to Assess the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler

Sex

All

Estimated Enrollment

28

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 06 Aug 2024
Estimated Primary Completion Date: 08 Oct 2024
Estimated Study Completion Date: 08 Oct 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria